Streetbeat News

Products Services

ACELYRIN

ACELYRIN, INC. has released its financial results for the third quarter of 2024 and announced that topline data from its Phase 2b/3 trial of izokibep for treating non-infectious non-anterior uveitis is expected in December 2024.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

VXRT

Vaxart has provided a business update and reported its Q3 2024 financial results. The company expects to complete enrollment for its COVID-19 Phase 2b study in November 2024. Vaxart is in a solid financial position to achieve regulatory and clinical milestones.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

MRK

Merck & Co., Inc. participated in the UBS Global Healthcare Conference, with key company figures discussing their roles and insights.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

CVV

CVD Equipment Corporation has received a $3.5 million follow-on order for a Chemical Vapor Infiltration system, which will be used to produce advanced materials for gas turbine engines.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

ADAP

Adaptimmune Therapeutics (NASDAQ: ADAP) reports Q3 2024 financial updates, highlighting the launch of Tecelra® with 9 treatment centers and the first patient apheresed. The company plans a 33% headcount reduction in Q1 2025 to save $300 million over four years, aiming for breakeven by 2027. Total liquidity at the end of Q3 was $186.1 million.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

TYRA

Tyra Biosciences, a clinical-stage biotech company, will present at the Jefferies London Healthcare Conference. CEO Todd Harris will participate in a fireside chat on November 19th, 2024.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

TSHA

Taysha Gene Therapies reported its Q3 2024 financial results and provided a corporate update. The high dose TSHA-102 was well tolerated in trials, with no serious adverse events or dose-limiting toxicities, leading to continued enrollment approval.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

CHWY

Chewy's stock has surged 96% in six months due to expansion initiatives, but investors should consider the impact of stiff competition and premium valuation on its near-term potential.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

AIRJ

AirJoule Technologies Corporation (NASDAQ: AIRJ) announced its third quarter 2024 results, highlighting its advancements in atmospheric water harvesting technology.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

BNGO

Bionano Genomics reported a 35% decrease in Q3 2024 revenue compared to Q3 2023, with $6.1 million in revenue. Despite this, the company saw a 22% increase in its installed base of optical genome mapping systems and a 27% increase in nanochannel array flowcell sales.

Portfolio Pulse from

November 13, 2024 | 9:15 pm